Demonstrated rapid, durable, and statistically significant improvement in depressive symptoms as measured by MADRS total score compared to placebo (p=0.002 on primary endpoint)
Statistically significant improvement at week 1 in MADRS total score compared to placebo (key secondary endpoint, p=0.007)
Statistically significant improvement versus placebo on all secondary endpoints at week 6, including remission (p